1. Home
  2. YORW vs CTNM Comparison

YORW vs CTNM Comparison

Compare YORW & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo York Water Company (The)

YORW

York Water Company (The)

HOLD

Current Price

$29.53

Market Cap

466.4M

Sector

Utilities

ML Signal

HOLD

Logo Contineum Therapeutics Inc.

CTNM

Contineum Therapeutics Inc.

HOLD

Current Price

$14.55

Market Cap

480.5M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
YORW
CTNM
Founded
1816
2009
Country
United States
United States
Employees
104
N/A
Industry
Water Supply
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
466.4M
480.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
YORW
CTNM
Price
$29.53
$14.55
Analyst Decision
Hold
Buy
Analyst Count
1
4
Target Price
$34.00
$19.00
AVG Volume (30 Days)
163.9K
264.8K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
3.13%
N/A
EPS Growth
N/A
0.46
EPS
0.33
N/A
Revenue
$77,488,000.00
N/A
Revenue This Year
$11.78
N/A
Revenue Next Year
$4.95
N/A
P/E Ratio
$88.39
N/A
Revenue Growth
3.37
N/A
52 Week Low
$28.26
$3.35
52 Week High
$34.30
$16.33

Technical Indicators

Market Signals
Indicator
YORW
CTNM
Relative Strength Index (RSI) 44.27 60.97
Support Level $28.26 $13.86
Resistance Level $32.13 $14.63
Average True Range (ATR) 0.61 0.91
MACD 0.01 0.24
Stochastic Oscillator 57.03 71.17

Price Performance

Historical Comparison
YORW
CTNM

About YORW York Water Company (The)

The York Water Co is the investor-owned water utility in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. The company also owns and operates three wastewater collection systems and twelve wastewater collection and treatment systems. The company operates within its franchised water and wastewater territory, which covers portions of municipalities within four counties in south-central Pennsylvania. It provides services to diversified, manufacturing such items as fixtures and furniture, electrical machinery, food products, paper, ordnance units, textile products, air conditioning systems, laundry detergent, barbells, and motorcycles.

About CTNM Contineum Therapeutics Inc.

Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.

Share on Social Networks: